French, non-interventional, retrospective, multicentric analysis of patients who have undergone a controlled ovarian stimulation (COS) for in-vitro fertilization (IVF)/ intracytoplasmic sperm injection (ICSI). The main objective is to determine the cumulative live birth rate with highly purified menotropin (HP-hMG) which is defined as the occurrence of live birth per started COS, further to transfer of fresh and frozen embryos generated from the same COS.
Study Type
OBSERVATIONAL
Enrollment
11,488
All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
Ferring investigational site
Bondy, France
Ferring investigational site
Clamart, France
Ferring investigational site
Créteil, France
Ferring investigational site
Le Chesnay, France
Cumulative live birth rate (cLBR)
Defined as the occurence of live birth per started COS, further to transfer of fresh and frozen embryos generated from the same COS.
Time frame: At delivery
Initial dose of Menotropin treatment per IVF cycle (IU)
Time frame: At Day 1 of Menotropin stimulation up to Day 20 of Menotropin stimulation during 2009 to 2016
Total dose of Menotropin treatment per IVF cycle (IU)
Time frame: At Day 1 of Menotropin stimulation up to Day 20 of Menotropin stimulation during 2009 to 2016
Total days of Menotropin treatment (per IVF cycle)
Duration of treatment (in days) with Menotropin of patients will be reported.
Time frame: Up to end of the ovarian stimulation treatment (up to 20 days) during 2009 to 2016
Dose adjustment of Menotropin in IU
Time frame: At Day 1 of Menotropin stimulation up to Day 20 of Menotropin stimulation during 2009 to 2016
Type of gonadotropin-releasing hormone (GnRH) protocols used for Luteinizing Hormone (LH) surge suppression (with in particular long and short agonist, and antagonist)
Gonadotropin-releasing hormone protocols with in particular long and short agonist, and antagonist.
Time frame: At the day of the first GnRH administration during the ovarian stimulation treatment (up to 20 days) in 2009 to 2016
Total days of LH surge suppression protocol
Gonadotropin-releasing hormone protocols with in particular long and short agonist, and antagonist.
Time frame: From Day 1 up to the last day of GnRH analogues administration during 2009 to 2016
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ferring investigational site
Lens, France
Ferring investigational site
Lyon, France
Ferring investigational site
Marseille, France
Ferring investigational site
Nice, France
Ferring investigational site
Rennes, France
Ferring investigational site
Rennes, France